Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Pathological Complete Response in Advanced Gastrointestinal Stromal Tumor after Imatinib Therapy
Bohuslav MELICHARZbynek VOBORILJan NOZICKAAles RYSKAHana URMINSKÁTomás VANECEKMichal MICHAL
Author information
JOURNALS OPEN ACCESS

2005 Volume 44 Issue 11 Pages 1163-1168

Details
Abstract

Gastrointestinal stromal tumor (GIST) is a rare neoplasm exhibiting, in most cases, mutations of c-kit. Recently it has been demonstrated that a majority of GIST patients with c-kit mutations respond to therapy with imatinib, a c-kit tyrosine kinase inhibitor. Although the response rate in patients treated with imatinib in prospective clinical studies is above 50%, complete response is rare, and the data on the use of imatinib as neoaduvant therapy facilitating radical surgery is still scanty. Here, we report on a patient with metastatic gastric GIST who underwent surgery after 6 months of imatinib therapy. No tumor cells were detected on pathological examination of resection specimen. This case report indicates that a pathological complete response could be achieved with imatinib therapy in patients with GIST, but a wider experience and longer follow-up is necessary to appreciate the prognostic significance of pathological complete response in GIST.

Information related to the author
© 2005 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top